The journey from Investigational New Drug (IND) submission to regulatory approval
represents one of the most complex, capital-intensive, and strategically sensitive
undertakings in the life sciences industry. In oncology—where science is advancing
rapidly, regulatory pathways are evolving, and patient populations are increasingly
molecularly defined—success requires far more than scientific innovation alone. It
demands deliberate planning across major development inflection points, rigorous
incremental evidence generation, early and continuous regulatory engagement,
and the disciplined application of Quality-by-Design (QbD) principles.
This white paper expands upon key insights shared during the OCT West Coast 2026
session and accompanying discussion, providing a structured, narrative-driven
framework for navigating critical transition points from Pre-IND through approval. It
integrates regulatory trends, translational strategy, CMC scalability, and precision
oncology considerations into a cohesive model designed to reduce risk, prevent
clinical holds, and strengthen approval probability.
Back to Resource Center